Contineum Therapeutics, a clinical-stage biotech focusing on neuroinflammation and immunology, recently initiated Phase 2 trials of PIPE-791 targeting idiopathic pulmonary fibrosis based on supportive Phase 1 data. Its pipeline also includes PIPE-307 for depression and multiple sclerosis under a partnership with Johnson & Johnson, which faces clinical setbacks in RRMS indications. The company's strategy leverages differentiated small molecule candidates but remains exposed to manufacturing supply risks due to reliance on contract manufacturers. Financially, Contineum maintains a strong liquidity position supporting ongoing operations.